Tags

Type your tag names separated by a space and hit enter

Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
Contraception. 1998 Nov; 58(5):321-2.C

Abstract

Recently, discussions focused on the question whether acquired activated (APC) resistance is a clue to the observed association between venous thromboembolism (VTE) risk and oral contraceptive (OC) use, especially with the so-called third-generation OC. The objective of our study was to check the validity of acquired APC resistance regarding VTE risk in a case-control study. Sixty-seven women with confirmed VTE diagnosis (n = 67) were consecutively ascertained in primary health care settings, interviewed and blood samples taken (at the earliest 6 months after VTE). Cases were age-matched to 290 population controls. Acquired APC resistance was measured as normalized APC ratio (APCRN). The effect of APC on tissue factor initiated thrombin generation was measured in plasma using alpha 2-macroglobulin attached thrombin activity as an endpoint. Higher risk (odds) ratio with 95% CI) of VTE for carriers of heterozygote Factor V Leiden mutation was confirmed [OR = 2.72 (CI:1.51-4.92)]. However, there is no association between VTE and the level of APCRN OR 0.65 (CI:0.35-1.22). We conclude that acquired APC resistance, measured with a tissue factor initiated test, is unlikely to have a direct association to the clinical outcome of venous thromboembolism.

Links

Publisher Full Text

Authors+Show Affiliations

Heinemann LA
ZEG-Centre for Epidemiology and Health Research, Zepernick, Germany. zeg@inx.de
Assmann A
No affiliation info available
Spannagl M
No affiliation info available
Schramm W
No affiliation info available
Dick A
No affiliation info available
Kluft C
No affiliation info available
de Maat MP
No affiliation info available

MeSH

AdolescentAdultCase-Control StudiesContraceptives, OralFactor VFemaleHumansMiddle AgedMutationOdds RatioProtein CRegression AnalysisRisk FactorsVenous Thrombosis

Pub Type(s)

Journal Article

Language

eng

PubMed ID

9883389

Citation

Heinemann, L A., et al. "Normalized Activated Protein C Ratio Itself Not Associated With Increased Risk of Venous Thromboembolism." Contraception, vol. 58, no. 5, 1998, pp. 321-2.
Heinemann LA, Assmann A, Spannagl M, et al. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism. Contraception. 1998;58(5):321-2.
Heinemann, L. A., Assmann, A., Spannagl, M., Schramm, W., Dick, A., Kluft, C., & de Maat, M. P. (1998). Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism. Contraception, 58(5), 321-2.
Heinemann LA, et al. Normalized Activated Protein C Ratio Itself Not Associated With Increased Risk of Venous Thromboembolism. Contraception. 1998;58(5):321-2. PubMed PMID: 9883389.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism. AU - Heinemann,L A, AU - Assmann,A, AU - Spannagl,M, AU - Schramm,W, AU - Dick,A, AU - Kluft,C, AU - de Maat,M P, PY - 1999/1/12/pubmed PY - 1999/1/12/medline PY - 1999/1/12/entrez KW - Biology KW - Blood Proteins KW - Case Control Studies KW - Contraception KW - Contraceptive Methods--pharmacodynamics KW - Developed Countries KW - Diseases KW - Embolism KW - Europe KW - Family Planning KW - Germany KW - Hemic System KW - Oral Contraceptives, Combined--pharmacodynamics KW - Oral Contraceptives--pharmacodynamics KW - Physiology KW - Research Methodology KW - Research Report KW - Risk Factors KW - Studies KW - Thromboembolism KW - Vascular Diseases KW - Western Europe SP - 321 EP - 2 JF - Contraception JO - Contraception VL - 58 IS - 5 N2 - Recently, discussions focused on the question whether acquired activated (APC) resistance is a clue to the observed association between venous thromboembolism (VTE) risk and oral contraceptive (OC) use, especially with the so-called third-generation OC. The objective of our study was to check the validity of acquired APC resistance regarding VTE risk in a case-control study. Sixty-seven women with confirmed VTE diagnosis (n = 67) were consecutively ascertained in primary health care settings, interviewed and blood samples taken (at the earliest 6 months after VTE). Cases were age-matched to 290 population controls. Acquired APC resistance was measured as normalized APC ratio (APCRN). The effect of APC on tissue factor initiated thrombin generation was measured in plasma using alpha 2-macroglobulin attached thrombin activity as an endpoint. Higher risk (odds) ratio with 95% CI) of VTE for carriers of heterozygote Factor V Leiden mutation was confirmed [OR = 2.72 (CI:1.51-4.92)]. However, there is no association between VTE and the level of APCRN OR 0.65 (CI:0.35-1.22). We conclude that acquired APC resistance, measured with a tissue factor initiated test, is unlikely to have a direct association to the clinical outcome of venous thromboembolism. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/9883389/Normalized_activated_protein_C_ratio_itself_not_associated_with_increased_risk_of_venous_thromboembolism_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0010-7824(98)00111-5 DB - PRIME DP - Unbound Medicine ER -